Results 241 to 250 of about 91,337 (260)

CD38-mediated ribosylation of proteins

The Journal of Immunology, 1995
Abstract The lymphocyte cell-surface Ag CD38 catabolizes NAD to adenosine 5' diphosphoribose (ADPR) and cyclic ADPR (cADPR). We show here that the soluble extracellular domain of CD38 (sCD38) mediates ADP ribosylation of several proteins. This was demonstrated by mass spectrometric analyses which revealed the addition of mass in units of
J C, Grimaldi, S, Balasubramanian, N H, Kabra, A, Shanafelt, J F, Bazan, G, Zurawski, M C, Howard   +6 more
openaire   +2 more sources

Kinetic competence of the cADP-ribose–CD38 complex as an intermediate in the CD38/NAD+ glycohydrolase-catalysed reactions: implication for CD38 signalling

Biochemical Journal, 2001
CD38/NAD+ glycohydrolase is a type II transmembrane glycoprotein widely used to study T- and B-cell activation and differentiation. CD38 is endowed with two different activities: it is a signal transduction molecule and an ectoenzyme that converts NAD+ into ADP-ribose (NAD+ glycohydrolase activity) and small proportions of cADP-ribose (cADPR; ADP ...
C, Cakir-Kiefer, H, Muller-Steffner, N, Oppenheimer, F, Schuber   +3 more
openaire   +2 more sources

Flavonoids as inhibitors of human CD38

Bioorganic & Medicinal Chemistry Letters, 2011
CD38 is a multifunctional enzyme which is ubiquitously distributed in mammalian tissues. It is involved in the conversion of NAD(P)(+) into cyclic ADP-ribose, NAADP(+) and ADP-ribose and the role of these metabolites in multiple Ca(2+) signaling pathways makes CD38 a novel potential pharmacological target.
Kellenberger, Esther, Kuhn, Isabelle, Schuber, Francis, Muller-Steffner, Hélène   +3 more
openaire   +3 more sources

CD38 Workshop: The genetic analysis of human CD38

1998
The aim of this study is the molecular genetic analysis of human CD38.
FERRERO, Enza, MALAVASI F.
openaire   +1 more source

Immunomodulatory effects of CD38-targeting antibodies

Immunology Letters, 2018
The fist in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of relapsed and refractory multiple myeloma. Based on the high activity and favorable toxicity profile of daratumumab, other CD38 antibodies, such as isatuximab, MOR202, and TAK-079, are being ...
openaire   +3 more sources

Topology of CD38

2000
DE FLORA, ANTONIO, FRANCO L, GUIDA, LUCREZIA, BRUZZONE, SANTINA, USAI C, ZOCCHI, ELENA   +5 more
openaire   +3 more sources

?????????????????????? rs6449182 ???????? cd38 ?? ???????? ???????????????? ???????????????????????? ????????????????????????

2014
???????? ???????????????????????? ??? ???????????????????? ???????? ???????????????? ???????????????????????? ??????- ?????????????????????? ?????????????? (??????) ?? ?????????????????????? ???? ???????????????????????? rs6449182 ???????? CD38. ?????????????????????? 249 ?????????????? ?????? ?? 238 ?????? ?????????????????????? ????????????, ?????????
openaire   +1 more source

CD38 in Hematopoiesis

2000
D, Campana, T, Suzuki, E, Todisco, A, Kitanaka   +3 more
openaire   +2 more sources

CD38

1997
A. Neil Barclay, Marion H. Brown, S.K. Alex Law, Andrew J. McKnight, Michael G. Tomlinson, P. Anton van der Merwe   +5 more
openaire   +1 more source

CD38

2016
openaire   +2 more sources